Date: July 19, 2025
The Q-TWiST analysis from the LITESPARK-005 trial showed statistically significant improvement of belzutifan over everolimus in patients with clear cell RCC.
Date: July 19, 2025
Patients with nonmetastatic esophageal cancer who received FLOT chemotherapy achieved a 3-year OS rate of 61.1% in an analysis of the phase 3 ESOPEC trial.
Date: July 19, 2025
Jacob E. Berchuck, MD, highlights novel findings pointing to androgen receptor signaling and Wnt pathway activation as key correlates of poor response to therapy.
Date: July 19, 2025
Researchers developed a CAR T-cell therapy to target CAIX/CD70 overexpression for patients with clear cell RCC.
Date: July 19, 2025
Glofitamab received a CRL from the FDA in R/R DLBCL, ODAC voted against belantamab mafodotin in R/R multiple myeloma, and more.
Date: July 19, 2025
Alicia Morgans, MD, MPH, discusses how the ARANOTE trial not only demonstrated clinical efficacy for the combination of ADT and darolutamide, but also highlighted key quality-of-life benefits that could help inform patient and physician conversations.
Date: July 19, 2025
JSKN003 demonstrated tolerability and antitumor activity in heavily pretreated HER2-positive breast cancer.
Date: July 18, 2025
A new biomarker, KIM-1, has the potential to show outcomes and response for patients with renal cell carcinoma.
Date: July 18, 2025
Patients with RCC who received 100 mg once daily casdatifan had an ORR of 33%, and those who received casdatifan plus cabozantinib had an ORR of 46%.
Date: July 18, 2025
Hans Hammers, MD, PhD, discusses the main efficacy differences between IO/TKI and IO/IO combinations in clear-cell renal cell carcinoma.
Date: July 18, 2025
Treatment with casdatifan in combination with cabozantinib produced responses and was safe in patients with pretreated clear cell renal cell carcinoma.
Date: July 18, 2025
High levels of CD163-positive TAMs and exhausted CD8-positive TILs could potentially affect efficacy results in metastatic RCC by reprogramming TAMs.
Date: July 18, 2025
Results from a Q-TWiST analysis of the LITESPARK-005 trial showed a trend favoring belzutifan over everolimus for patients with clear cell RCC.
Date: July 18, 2025
Hope S. Rugo, MD, discusses the safety profile of alpelisib for the treatment of PI3K-mutant HR-positive/HER2-negative advanced breast cancer.
Date: July 18, 2025
Luke Maese, DO, discusses how the evolution of AYA and adult ALL management may be inspired by treatment protocols used in the pediatric population.
Date: July 18, 2025
KIM-1 levels have shown the ability to predict therapeutic benefit in patients with renal cell carcinoma.
Date: July 18, 2025
Ritesh R. Kotecha, MD, discusses the rationale for targeting ENPP3 in clear cell renal cell carcinoma.
Date: July 18, 2025
A phase 2 trial shows promising safety results for carotuximab in treating advanced prostate cancer, offering hope for patients with limited options.
Date: July 18, 2025
Findings from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.
Date: July 18, 2025
Data from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.
Date: July 18, 2025
A genetically engineered herpes simplex virus plus immunotherapy reduces or eliminates tumors in 1/3 of clinical trial patients, according to a new study.
Date: July 18, 2025
Immunotherapy shows promise in reducing recurrence rates for high-risk skin cancer, despite mixed results in recent clinical trials.
Date: July 18, 2025
The FDA issued a CRL to the application for glofitamab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.
Date: July 18, 2025
Joshua K. Sabari, MD, discusses response rates observed with zidesamtinib in patients with advanced ROS1-positive non–small cell lung cancer.
Date: July 18, 2025
The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.
Date: July 18, 2025
Following the FDA ODAC's vote against belantamab mafodotin-based combinations in relapsed/refractory multiple myeloma, George Mulligan, PhD, provides insight into the agent's potential path foward.
Date: July 18, 2025
Luspatercept plus a concomitant JAK inhibitor didn’t meet the primary end point of 12-week RBC transfusion independence in myelofibrosis-associated anemia.
Date: July 18, 2025
Date: July 18, 2025
ICT01 has received orphan drug designation from the FDA for the treatment of patients with acute myeloid leukemia.
Date: July 18, 2025
Karie Danielle Keera Runcie, MD, discusses treatment challenges after progression on adjuvant therapy and the potential role for zanzalintinib in renal cell carcinoma.
Date: July 18, 2025